Director, Early S&E — Hematology & CV/Renal Innovation

Darum lohnt es sich

Embedded within each Therapeutic Area Leadership Team (TALT), these leaders will identify and advance high-potential assets from preclinical through Phase 1 clinical stages, shape early partnering strategies, and drive transactions in collaboration with Business Development /ppWe have a hybrid office/home working model.

NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations /liliDevelop and execute early partnering strategies, including onboarding approaches and competitive positioning for priority assets. /liliDrive cross-functional due diligence for each opportunity, coordinating scientific, clinical, regulatory, and commercial assessments to inform governance decisions. /liliTransaction Execution: Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution /liliRepresent the TA externally, leading sourcing activities at specialized conferences and cultivating relationships with biotech, academia, and investment communities. /li /ulh3Qualifications Experience Requirements /h3ulliSignificant tenure in biopharma with significant experience in external innovation, search evaluation, or business development. /liliAdvanced degree required (PhD, MD, or equivalent). /liliMust have Deep scientific expertise in Hematology or Cardiovascular/Renal therapeutic areas. /liliProven track record of leading due diligence and closing early-stage deals. /liliStrong network within biotech, academia, and pharma BD organizations. /li /ul /p #J-18808-Ljbffr ppTwo Directors of Search Evaluation to lead strategic sourcing and evaluation of external innovation opportunities in Hematology, and Cardiovascular/Renal therapeutic areas.

The position will be based in Zurich (preferred), Maidenhead, UK, KOP or Waltham (US) with significant business travel /pulliServe as the senior Early SE leader within the TALT, influencing therapeutic strategy and ensuring external innovation priorities are integrated into portfolio planning. /liliLead proactive sourcing and scouting efforts for preclinical and Phase 1 assets, building a robust pipeline of opportunities aligned with TA strategy. /liliCo-lead internal meetings (with Late Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas.